{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-034506","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.389463+00:00","generated_at":"2026-05-17T06:57:47.578455+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Gyre Therapeutics posts corporate presentation; no material financial or pipeline details provided","bullets":["Updated corporate presentation posted on company website as of Sept 10, 2025.","Presentation prepared for H.C. Wainwright Global Investment Conference in September 2025.","Filing text and exhibit excerpt do not disclose any new financial data or pipeline milestones.","Company focus remains anti-fibrotic therapeutics for chronic organ diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-034506","json":"https://secwatch.observer/filing/0001140361-25-034506.json","markdown":"https://secwatch.observer/filing/0001140361-25-034506.md","text":"https://secwatch.observer/filing/0001140361-25-034506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/0001140361-25-034506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/ef20055378_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:57:47.578455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}